UY38349A - Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met - Google Patents
Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y metInfo
- Publication number
- UY38349A UY38349A UY0001038349A UY38349A UY38349A UY 38349 A UY38349 A UY 38349A UY 0001038349 A UY0001038349 A UY 0001038349A UY 38349 A UY38349 A UY 38349A UY 38349 A UY38349 A UY 38349A
- Authority
- UY
- Uruguay
- Prior art keywords
- tam
- inhibitors
- pyrazolo
- pyridine compounds
- met kinases
- Prior art date
Links
- 108091000080 Phosphotransferase Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 102000020233 phosphotransferase Human genes 0.000 title abstract 2
- 150000005230 pyrazolo[3,4-b]pyridines Chemical class 0.000 title 1
- 229940125895 MET kinase inhibitor Drugs 0.000 abstract 1
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 229940043355 kinase inhibitor Drugs 0.000 abstract 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención se refiere a compuestos de la Fórmula I: I y estereoisómeros, tautómeros y sales de los mismos farmacéuticamente aceptables, en donde R1, R2, R9, X1 y G son como se definen en la presente, los cuales son inhibidores de una o más cinasas TAM y/o cinasa c-Met, y son útiles en el tratamiento y prevención de enfermedades las cuales pueden ser tratadas con un inhibidor de cinasa TAM y/o un inhibidor de cinasa c-Met.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862724829P | 2018-08-30 | 2018-08-30 | |
| US201962858686P | 2019-06-07 | 2019-06-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY38349A true UY38349A (es) | 2020-03-31 |
Family
ID=67928919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001038349A UY38349A (es) | 2018-08-30 | 2019-08-28 | Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US11104676B2 (es) |
| EP (1) | EP3843850B1 (es) |
| JP (2) | JP6970859B2 (es) |
| KR (1) | KR20210049898A (es) |
| CN (1) | CN112930215A (es) |
| AU (3) | AU2019330017B2 (es) |
| BR (1) | BR112021002722A2 (es) |
| CA (1) | CA3110502C (es) |
| CL (1) | CL2021000467A1 (es) |
| CO (1) | CO2021002651A2 (es) |
| CR (1) | CR20210098A (es) |
| CU (1) | CU20210015A7 (es) |
| DO (1) | DOP2021000038A (es) |
| EC (1) | ECSP21012498A (es) |
| IL (1) | IL281127B2 (es) |
| MA (1) | MA53487A (es) |
| MX (1) | MX2021001952A (es) |
| NI (1) | NI202100007A (es) |
| PE (1) | PE20211779A1 (es) |
| PH (1) | PH12021500017A1 (es) |
| SG (1) | SG11202101148UA (es) |
| TW (1) | TW202024071A (es) |
| UY (1) | UY38349A (es) |
| WO (1) | WO2020047184A1 (es) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200039938A1 (en) | 2017-03-30 | 2020-02-06 | Albert-Ludwigs-University Freiburg | Kdm4 inhibitors |
| AU2019323455B9 (en) * | 2018-08-24 | 2024-10-24 | Transthera Sciences (Nanjing), Inc. | Novel quinoline derivative inhibitor |
| TWI817018B (zh) | 2019-06-28 | 2023-10-01 | 美商艾瑞生藥股份有限公司 | 用於治療ｂｒａｆ相關的疾病和失調症之化合物 |
| AU2020342108B2 (en) | 2019-09-06 | 2024-03-07 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Compound having Axl and c-Met kinase inhibitory activity, preparation thereof and application thereof |
| WO2021057782A1 (zh) * | 2019-09-24 | 2021-04-01 | 南京药捷安康生物科技有限公司 | 杂环衍生物及其用途 |
| US12371428B2 (en) | 2019-09-26 | 2025-07-29 | Exelixis, Inc. | Pyridone compounds and methods of use |
| IL296060A (en) | 2020-03-03 | 2022-10-01 | Array Biopharma Inc | Use of (r)-n-(3-fluoro-4-((3-((1-hydroxypropan-2-yl)amino)-1h-pyrazolo[3,4-b]pyridin-4-yl)oxy) phenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide for cancer treatment |
| WO2022007921A1 (zh) | 2020-07-10 | 2022-01-13 | 北京范恩柯尔生物科技有限公司 | 三嗪类化合物及其组合物和用途 |
| US20250025451A1 (en) * | 2021-04-09 | 2025-01-23 | Celgene Corporation | Treatment of cancer with kdm4 inhibitors |
| US20240293386A1 (en) * | 2021-06-22 | 2024-09-05 | Lg Chem, Ltd. | Novel compound as protein kinase inhibitor |
| WO2023002360A1 (en) | 2021-07-22 | 2023-01-26 | Pfizer Inc. | Solid forms and formulations of an inhibitor of tam and c-met kinases |
| IT202100022682A1 (it) * | 2021-09-01 | 2023-03-01 | Luigi Frati | Derivati pirimidinici e loro uso nel trattamento di tumori |
| CN115850301B (zh) * | 2021-09-24 | 2024-11-15 | 中山医诺维申新药研发有限公司 | 吡唑酮类化合物及其组合物和用途 |
| EP4427747A4 (en) * | 2021-11-05 | 2025-09-17 | Haihe Biopharma Co Ltd | SOLID DISPERSION, PREPARATION METHOD THEREOF AND SOLID FORMULATION CONTAINING IT |
| WO2023078408A1 (zh) * | 2021-11-05 | 2023-05-11 | 上海海和药物研究开发股份有限公司 | 含met受体酪氨酸激酶抑制剂的药物组合及应用 |
| AU2022413540A1 (en) | 2021-12-16 | 2024-07-18 | Kinnate Biopharma Inc. | Inhibitors of met kinase |
| CA3242732A1 (en) * | 2021-12-29 | 2023-07-06 | Beijing Avistone Biotechnology Co., Ltd. | Heteroaromatic nitrogen-oxide compound, preparation method therefor and use thereof |
| MX2024008057A (es) | 2021-12-30 | 2024-08-28 | Biomea Fusion Inc | Compuestos de pirazina como inhibidores de flt3. |
| KR20250164828A (ko) | 2023-03-30 | 2025-11-25 | 레볼루션 메디슨즈, 인크. | Ras gtp 가수분해 유도를 위한 조성물 및 이의 용도 |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| CN116768868B (zh) * | 2023-08-15 | 2023-12-08 | 云南省药物研究所 | 一种哒嗪酮硫代衍生物及其制备方法和应用 |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| CN118878515B (zh) * | 2024-06-19 | 2025-10-28 | 河北科技大学 | 一种取代苯胺嘧啶类化合物及其制备方法和用途 |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US20050288290A1 (en) | 2004-06-28 | 2005-12-29 | Borzilleri Robert M | Fused heterocyclic kinase inhibitors |
| AU2005270068B2 (en) | 2004-07-02 | 2012-04-19 | Exelixis, Inc. | C-Met modulators and method of use |
| PE20061119A1 (es) | 2005-01-19 | 2006-11-27 | Aventis Pharma Sa | PIRAZOLO PIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE CINASAS FAK, KDR Y Tie |
| EP2001880A2 (en) * | 2006-03-07 | 2008-12-17 | Array Biopharma, Inc. | Heterobicyclic pyrazole compounds and methods of use |
| CN102816175B (zh) | 2011-06-09 | 2015-12-16 | 上海汇伦生命科技有限公司 | 一种杂环并吡啶酮类化合物,其中间体、制备方法和用途 |
| WO2013032797A2 (en) * | 2011-08-26 | 2013-03-07 | New Hope R & D Bioscience, Inc. | Oxetane 3,3-dicarboxamide compounds and methods of making and using same |
| JP2014534949A (ja) * | 2011-09-19 | 2014-12-25 | ジェネンテック， インコーポレイテッド | Ｃ−ｍｅｔアンタゴニストおよびｂ−ｒａｆアンタゴニストを含む組合せ処置 |
| UA114900C2 (uk) * | 2011-11-14 | 2017-08-28 | Ігніта, Інк. | Похідні урацилу як інгібітори axl і c-met-кінази |
| JP2016527274A (ja) | 2013-08-02 | 2016-09-08 | イグナイタ インコーポレイテッド | ＡＸＬ／ｃＭＥＴ阻害剤を単独または他の薬剤と組み合わせて用いて各種がんを治療する方法 |
| HUE037579T2 (hu) * | 2013-12-26 | 2018-09-28 | Ignyta Inc | Pirazolo[1,5-a]piridin-származékok és módszerek alkalmazásukra |
| TW201613919A (en) | 2014-07-02 | 2016-04-16 | Pharmacyclics Llc | Inhibitors of Bruton's tyrosine kinase |
| AU2015294889B2 (en) | 2014-07-31 | 2018-03-15 | Novartis Ag | Combination therapy |
| GB201509338D0 (en) | 2015-05-29 | 2015-07-15 | Bergenbio As | Combination therapy |
| KR101829998B1 (ko) | 2015-11-04 | 2018-02-19 | 롬엔드하스전자재료코리아유한회사 | 착색 감광성 수지 조성물 및 이를 이용한 차광성 스페이서 |
| EP4321513A3 (en) * | 2016-03-28 | 2024-05-08 | Incyte Corporation | Pyrrolotriazine compounds as tam inhibitors |
| US20190269666A1 (en) | 2016-07-29 | 2019-09-05 | Eli Lilly And Company | Combination therapy with merestinib and anti-pd-l1 or anti-pd-1 inhibitors for use in the treatment of cancer |
| US20190185567A1 (en) | 2016-08-01 | 2019-06-20 | Ignyta, Inc. | Combinations for the treatment of cancer |
| CN109715157A (zh) | 2016-08-24 | 2019-05-03 | 亚尼塔公司 | 用于治疗癌症的组合 |
| CN109982700A (zh) | 2016-11-16 | 2019-07-05 | 伊莱利利公司 | 具有外显子14跳跃突变或外显子14跳跃表型的癌症的治疗 |
| CN108250200A (zh) | 2016-12-28 | 2018-07-06 | 中国科学院上海药物研究所 | 一种具有Axl抑制活性的化合物及其制备和应用 |
| JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
| EP3719012B1 (en) | 2017-11-24 | 2024-03-06 | Medshine Discovery Inc. | N-[4-[(2-amino-4-pyridinyl)oxy]-3-fluorophenyl]-3-(4-fluorophenyl)-1,2,3,4-tetrahydro-2,4-dioxo-5-pyrimidinecarboxamide derivatives as c-met/axl inhibitors for the treatment of tumors |
| US11247990B1 (en) | 2017-12-07 | 2022-02-15 | Array Biopharma Inc | Bicyclic fused pyridine compounds as inhibitors of TAM kinases |
-
2019
- 2019-08-28 UY UY0001038349A patent/UY38349A/es not_active Application Discontinuation
- 2019-08-29 MA MA053487A patent/MA53487A/fr unknown
- 2019-08-29 EP EP19766425.3A patent/EP3843850B1/en active Active
- 2019-08-29 CR CR20210098A patent/CR20210098A/es unknown
- 2019-08-29 US US16/555,432 patent/US11104676B2/en active Active
- 2019-08-29 IL IL281127A patent/IL281127B2/en unknown
- 2019-08-29 CU CU2021000015A patent/CU20210015A7/es unknown
- 2019-08-29 MX MX2021001952A patent/MX2021001952A/es unknown
- 2019-08-29 WO PCT/US2019/048701 patent/WO2020047184A1/en not_active Ceased
- 2019-08-29 SG SG11202101148UA patent/SG11202101148UA/en unknown
- 2019-08-29 JP JP2021510177A patent/JP6970859B2/ja not_active Expired - Fee Related
- 2019-08-29 PE PE2021000248A patent/PE20211779A1/es unknown
- 2019-08-29 AU AU2019330017A patent/AU2019330017B2/en not_active Ceased
- 2019-08-29 BR BR112021002722-0A patent/BR112021002722A2/pt not_active Application Discontinuation
- 2019-08-29 CA CA3110502A patent/CA3110502C/en active Active
- 2019-08-29 TW TW108131145A patent/TW202024071A/zh unknown
- 2019-08-29 KR KR1020217009262A patent/KR20210049898A/ko not_active Abandoned
- 2019-08-29 CN CN201980071473.1A patent/CN112930215A/zh active Pending
-
2021
- 2021-02-09 NI NI202100007A patent/NI202100007A/es unknown
- 2021-02-23 PH PH12021500017A patent/PH12021500017A1/en unknown
- 2021-02-23 EC ECSENADI202112498A patent/ECSP21012498A/es unknown
- 2021-02-24 CL CL2021000467A patent/CL2021000467A1/es unknown
- 2021-02-26 DO DO2021000038A patent/DOP2021000038A/es unknown
- 2021-02-26 CO CONC2021/0002651A patent/CO2021002651A2/es unknown
- 2021-07-15 US US17/376,571 patent/US11780835B2/en active Active
- 2021-10-29 JP JP2021177253A patent/JP7337133B2/ja active Active
-
2022
- 2022-05-03 AU AU2022202946A patent/AU2022202946B2/en not_active Ceased
- 2022-08-25 AU AU2022221514A patent/AU2022221514B2/en not_active Expired - Fee Related
-
2023
- 2023-08-29 US US18/457,795 patent/US20240174666A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021002651A2 (es) | Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met | |
| CO2019004650A2 (es) | Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret | |
| CL2018000119A1 (es) | Compuestos pirazolo[1,5-a]piridina sustituidos como inhibidores de quinasa de ret. | |
| MX388140B (es) | Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret. | |
| MX2020003552A (es) | Formas cristalinas. | |
| MX2020012520A (es) | Macrociclos con grupos p2' heterociclicos como inhibidores del factor xia. | |
| AR111233A1 (es) | Inhibidores de tyk2, usos y métodos para la producción de los mismos | |
| UY32192A (es) | COMPUESTOS PIRAZOLO[1,5-a]PIRIMIDINA SUSTITUIDA COMO INHIBIDORES DE TRK CINASA | |
| CO2019001181A2 (es) | Compuestos de heteroarilcarboxamida como inhibidores de ripk2 | |
| CO2021008535A2 (es) | Compuestos de quinolina como inhibidores de quinasas tam y met | |
| CO2021000782A2 (es) | Agentes inhibidores de ask1 | |
| EA202190393A1 (ru) | СОЕДИНЕНИЯ ПИРАЗОЛО[3,4-b]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ TAM- И Met-КИНАЗ | |
| EA201990939A1 (ru) | ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРИДИНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20240529 |